Thermo Fisher Scientific Inc. (NYSE:TMO) reported first-quarter 2025 adjusted earnings per share of $5.15 on Wednesday, beating the street view of $5.10.
Quarterly sales of $10.36 billion, almost flat year over year, outpaced the analyst consensus estimate of $10.23 billion. Organic revenue growth was 1%.
“We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I’m incredibly proud of our team’s execution,” said Marc Casper, chairman, president, and CEO of Thermo Fisher Scientific. “Our team leveraged the PPI Business System to drive operational excellence and enable our customers’ success.”
Casper added: “Thermo Fisher is incredibly well-positioned. Our experienced management team has a proven track record, and as the trusted partner to our customers, we will help them manage the current environment, identifying new opportunities and ultimately creating value for all our stakeholders.”
Also Read: 3M Spin-Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy
Thermo Fisher’s adjusted operating income for the first quarter of 2025 was $2.27 billion, compared with $2.28 billion in the year-ago quarter.
Revenue from the Life Sciences Solutions Segment increased by 2.5% year over year to $2.34 billion. Analytical Instruments Segment sales were up 1.8% to $1.72 billion.
Specialty Diagnostics Segment revenues increased 3.5% to $1.15 billion, and Laboratory Products and Biopharma Services segment sales were down 1.5% at $5.64 billion.
Thermo Fisher Scientific agreed to acquire Solventum’s (NYSE:SOLV) Purification & Filtration business in February for approximately $4.1 billion in cash.
Solventum's Purification & Filtration business provides purification and filtration technologies for the production of biologics, medical technologies, and industrial applications.
Price Action: Thermo Fisher stock is trading 4.23% higher at $453.10 at the last check Wednesday.
Read Next:
Image: Shutterstock
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。